Todas as matérias desta seção, das mais recentes às mais antigas — página 163 de 371.
Teledyne Technologies (NYSE:TDY) announced today that its subsidiary, Teledyne FLIR Defense, has been awarded an $11.2 million contract by the U.S. Army’s Capability Program Executive for Chemical, Biological, Radiological and Nuclear Defense (CPE CBRND).
Ciena (NYSE:CIEN) reported robust financial results for its fiscal second quarter ended May 2, 2026, showcasing the impact of escalating global demand for high-speed connectivity solutions.
The Buckle (NYSE:BKE) reported positive sales figures for the four-week fiscal month ended May 30, 2026, marking a continued period of growth for the retailer.
Caleres (NYSE:CAL), a portfolio of consumer-driven footwear brands, reported financial results for the first quarter of 2026 today, highlighted by a significant performance gap between its wholesale brand operations and its retail footprint.
Bio-Techne (NASDAQ:TECH) and Refeyn have launched a new integrated analytical workflow designed to streamline the characterization of complex biologics.
Columbus McKinnon (NASDAQ:CMCO) reported its financial results for the fourth quarter and full fiscal year 2026 today, highlighting the substantial impact of its recent Kito Crosby acquisition.
MarketAxess Holdings (NASDAQ:MKTX) saw a broad rebound in trading volumes across most product categories during May 2026, recovering from levels recorded in April.
Somnigroup International (NYSE:SGI) announced today that its proposed acquisition of Leggett & Platt (NYSE:LEG) has cleared a significant regulatory hurdle.
X-energy (NASDAQ:XE) reported total revenues and grant income of $43.4 million for the first quarter of 2026, marking a 109% increase compared to the same period in 2025.
Alvotech (NASDAQ:ALVO) has officially resubmitted its Biologics License Applications (BLAs) to the U.S. Food and Drug Administration (FDA) for two of its lead biosimilar candidates: AVT05, a proposed biosimilar to Simponi and Simponi Aria (golimumab), and AVT06, a proposed biosimilar to Eylea (aflibercept) 2 mg.
111 (NASDAQ:YI) reported unaudited financial results for the first quarter of 2026 today, signaling the company's deepening transition toward a more lean and technology-oriented operating structure.
Biogen (NASDAQ:BIIB) and UCB have announced the release of positive results from the Phase 3 PHOENYCS GO clinical trial evaluating dapirolizumab pegol (DZP), an investigational treatment for systemic lupus erythematosus (SLE).
Pharming Group (NASDAQ:PHAR) announced today that the U.S. Food and Drug Administration (FDA) has accepted its resubmitted supplemental New Drug Application (sNDA) for Joenja (leniolisib).
GloBra’s patent covering the Chain Code Technology and Parallel Token Solution used in GLBrain and GLMall has finally been approved by both the European and United States patent offices.
The grants are registered under European Patent EP 3 857 405 B1 and US Patent 12,430,644.
Broadcom (NASDAQ:AVGO) reported strong financial results for the second quarter of fiscal year 2026, underscored by exceptional growth in its semiconductor segment.
CrowdStrike Holdings (NASDAQ:CRWD) has reported its financial results for the first quarter of fiscal 2027, ended April 30, 2026, showcasing sustained growth and improved operational profitability.
Five Below (NASDAQ:FIVE) reported robust financial results for the first quarter of fiscal 2026, characterized by high double-digit growth in both top-line revenue and comparable store sales.
Crude oil prices extended gains on Wednesday, rising approximately 2% as market participants reacted to a significant escalation in Middle East hostilities and a breakdown in diplomatic communication between Tehran and Washington.
GitLab (NASDAQ:GTLB) has confirmed the layoff of approximately 350 employees, representing 14% of its workforce, as the company implements a restructuring plan designed to align its operations with the evolving demands of artificial intelligence.
Eli Lilly and Company (NYSE:LLY) has announced a significant research and licensing collaboration with Ascidian Therapeutics aimed at developing novel treatments for inherited kidney diseases.
Novo Nordisk (NYSE:NVO) has launched its oral Wegovy weight loss medication in the United Arab Emirates (UAE), marking the first international rollout of the drug outside the United States.
RTX (NYSE:RTX) announced today that its Raytheon business has been awarded a $515 million follow-on contract from the U.S. Navy to continue the production and integration of the SPY-6 family of radars.
Kura Oncology (NASDAQ:KURA) has released preliminary Phase 1a data showcasing the potential of its next-generation farnesyl transferase inhibitor (FTI), darlifarnib, as a foundational component of combination therapies for KRAS-mutant cancers.
Oshkosh Defense, a business unit of Oshkosh Corporation (NYSE:OSK), has been awarded new orders valued at $142 million for its Family of Medium Tactical Vehicles (FMTV) A2 platform.
